Open AccessIn Early Research, CLL Patients Appear to Benefit from Isoform-Specific PI3K Inhibitor
Author(s) -
Rabiya S. Tuma
Publication year - 2013
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000431866.53659.a4
Subject(s) - idelalisib , medicine , chronic lymphocytic leukemia , population , clinical trial , oncology , cancer , leukemia , ibrutinib , environmental health